Drug Trial Radar · NCT06588660
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Dec 18, 2024
Primary completion
Feb 14, 2025
Study completion Feb 14, 2025
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Simcha Therapeutics
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase Ib trial tests the safety, side effects and best dose of ST-067 in combination with teclistamab and how well it works in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). ST-067 is an engineered variant of the human cytokine interleukin-18 that may help the immune system kill cancer cells. Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen (BCMA), a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Giving ST-067 in combination with teclistamab may be safe, tolerable and/or effective in treating patients with relapsed or refractory multiple myeloma.
Conditions
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma
Interventions
VevoctadekinBiological
Given SC
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration and biopsy
Bone Marrow BiopsyProcedure
Undergo bone marrow aspiration and biopsy
Medical Chart ReviewOther
Ancillary studies
TeclistamabDrug
Given SC
Biospecimen CollectionProcedure
Undergo blood sample collection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Monotherapy dose-limiting toxicities (DLT) ratesTime frame: Up to 28 days (cycle 1)
- Combination therapy DLT ratesTime frame: Up to 28 days (cycle 2)
- Optimal biological dose (OBD)Time frame: Up to 28 days
- Incidence of adverse events (AEs)Time frame: Up to 30 days after last dose of ST-067
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.